Form 4: Poplar Point Capital Partners LP Increases Stake in NovaBay Pharmaceuticals
SEC Form 4 Filing
Poplar Point Capital Partners LP, along with related entities and Jad Fakhry, reports acquiring additional shares of NovaBay Pharmaceuticals, increasing their holdings to 991,569 shares.
Summary
- Poplar Point Capital Partners LP, Poplar Point Capital Management LLC, Poplar Point Capital GP LLC, and Jad Fakhry jointly filed a Form 4.
- The filing reports purchases of NovaBay Pharmaceuticals common stock between March 26, 2025, and April 1, 2025.
- The purchases were made at prices ranging from $0.585 to $0.615 per share.
- Following these transactions, the reporting entities collectively beneficially own 991,569 shares of NovaBay Pharmaceuticals common stock.
- The filing clarifies that it should not be construed as an admission of beneficial ownership beyond the securities actually owned by each person.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it simply reflects a change in ownership reported through a regulatory filing. It doesn't inherently indicate positive or negative prospects for the company.
Positives
- Increased investment by Poplar Point Capital Partners could signal confidence in NovaBay Pharmaceuticals.
- The purchases occurred at prices between $0.585 and $0.615, indicating a willingness to invest at these levels.
Risks
- The filing explicitly states that it should not be construed as an admission of beneficial ownership, which could suggest a complex ownership structure.
- The Form 4 filing indicates a change in ownership, which may introduce uncertainty.
Industry Context
Form 4 filings are standard disclosures required by the SEC when insiders or significant shareholders of a publicly traded company buy or sell shares. This filing indicates changes in the ownership structure of NovaBay Pharmaceuticals.
Stakeholder Impact
- Shareholders may react to the increased stake by Poplar Point Capital Partners, potentially influencing the stock price.
- The filing provides transparency to the market regarding insider transactions.
Key Dates
| Date | Description |
|---|---|
| 03/26/2025 | First reported transaction date; purchase of 13,292 shares at $0.609. |
| 03/27/2025 | Purchase of 18,504 shares at $0.615 and 600 shares at $0.609. |
| 03/28/2025 | Purchase of 49,400 shares at $0.6124. |
| 03/31/2025 | Purchase of 21,654 shares at $0.59. |
| 04/01/2025 | Purchase of 19,915 shares at $0.585. |
| 04/14/2025 | Date of signature for the Form 4 filing. |
Keywords
NovaBay Pharmaceuticals, Poplar Point Capital Partners, Jad Fakhry, Form 4, Beneficial Ownership, Stock Acquisition
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.